1

Working to address key unmet needs across a number of cancer types

Despite many recent advances in cancer treatments with breakthrough therapies, a large proportion of patients unfortunately develop resistance to their current treatment and are in need of new options. We at ORIC are committed to addressing this unmet medical need.
Our commitment includes conducting clinical trials with our investigational medicines to demonstrate their safety and efficacy. Data from these clinical trials ultimately could support regulatory approval, allowing these medicines to become available for the benefit of many cancer patients.
Patients who choose to participate in clinical trials play a critical role in the development of these and other new medicines. If you are interested in gaining access to our investigational medicines, we encourage you to speak with your physician about the possibility of enrolling in a clinical trial.

CLINICAL TRIALS NOW ENROLLING

ORIC-533, ORIC-114, and ORIC-944 are investigational drug candidates and have not been approved for marketing by the US FDA or other regulatory authorities.

Phase 1b Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma
• Currently enrolling in the United States
Phase 1b Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
• Currently enrolling in the Republic of Korea
Phase 1b Study of ORIC-944 in Patients with Metastatic Prostate Cancer
• Currently enrolling in the United States